# Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

> **NCT04770688** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Chest Hospital** · enrollment: 25 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer With EGFR Mutation
- Locally Advanced Solid Tumor
- Metastatic Cancer
- Adenocarcinoma of Lung

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04770688
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-19
- **Primary completion:** 2024-06-20
- **Final completion:** 2024-06-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770688, "Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04770688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*